UCB traded at 261.00 this Thursday April 2nd, decreasing 6.80 or 2.54 percent since the previous trading session. Looking back, over the last four weeks, UCB lost 3.20 percent. Over the last 12 months, its price rose by 62.26 percent. Looking ahead, we forecast UCB to be priced at 245.65 by the end of this quarter and at 227.54 in one year, according to Trading Economics global macro models projections and analysts expectations.
Ucb SA is a Belgium-based biopharmaceutical and specialty chemical company that specializes in two therapeutic areas: diseases of the central nervous system (CNS) and immunology. In the area of central nervous system disorders, the Company is focused on epilepsy, diabetic neuropathic pain, multiple sclerosis, fibromyalgia, restless legs syndrome and Parkinson’s disease, and the area of immunology includes, bone loss disorders, Crohn’s disease, rheumatoid arthritis and respiratory disease. In addition to its core fields of business, Ucb SA delivers molecule solutions to specialists for use in the treatment of severe diseases. Its product portfolio includes drugs, such as Neupro, Vimpat, Cimzia, among others. Ucb SA also operates in primary care to support specialist products that are administered by primary care physicians.